Skip to content
  1. Home
  2. >Test Catalog Resources
  3. >Test Catalog
  4. >Hereditary Cancer
  5. >Helix Hereditary Multi Cancer Panel

Helix Hereditary Multi-Cancer Panel

Test Description

This panel evaluates 70 genes associated with hereditary cancer conditions that predispose to a variety of primarily adult-onset solid tumors across many organ systems including: breast, gynecologic (ovarian and uterine), colorectal, pancreatic, prostate, kidney, skin, brain and nervous system, and endocrine glands (adrenal, pituitary, parathyroid, thyroid).

To view the complete test description of this test, click here

Genes Tested (70)

AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, CTNNA1, DICER1, EGFR, EPCAM, FH, FLCN, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL


Important Test Information


Ordering Information

Turnaround time: 7-24 days


Preferred specimen: 3mL Lavender top (BD Vacutainer EDTA)


Shipping instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.


Clinical Description

This panel includes genes that have an established association with multiple cancer types including breast, colorectal, uterine, ovarian, prostate, kidney, pancreatic, skin, endocrine glands (thyroid, parathyroid, pituitary, adrenal), and nervous system. These genes are primarily associated with adult-onset solid tumors, although some may develop in childhood.


The genes on this panel were specifically selected for their established association with hereditary cancer predisposition. Identification of a pathogenic variant may facilitate increased cancer screening and preventative surgery for early-detection and prevention. Identification of a pathogenic variant also helps identify at-risk family members, who can pursue genetic testing and preventive measures.


The genes on this panel are associated with conditions that have autosomal dominant and/or autosomal recessive inheritance. Note that some of these genes may also be associated with other unrelated conditions; this means that when undergoing this test, there is a possibility of incidentally detecting carrier status for, or predisposition to, one of these conditions.


Analyzing a wide range of genes in a single test can provide an efficient, cost-effective method of testing for several hereditary cancer conditions. This approach increases the chance of identifying the underlying diagnosis responsible for an individual’s or family’s cancer predisposition.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.


Share